NASDAQ:NVNO enVVeno Medical (NVNO) Stock Forecast, Price & News $3.16 +0.19 (+6.40%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.87▼$3.1750-Day Range$2.91▼$5.1952-Week Range$2.83▼$7.93Volume45,519 shsAverage Volume51,673 shsMarket Capitalization$29.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About enVVeno Medical (NASDAQ:NVNO) StockenVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Read More Receive NVNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enVVeno Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address NVNO Stock News HeadlinesMay 1, 2023 | benzinga.comenVVeno Medical Q1 2023 Ended Quarter With $34.2M In CashMay 1, 2023 | finance.yahoo.comenVVeno Medical Reports First Quarter 2023 Financial Results and Provides Corporate UpdateJune 4, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.April 30, 2023 | americanbankingnews.comenVVeno Medical (NASDAQ:NVNO) Trading Down 3.5%March 22, 2023 | americanbankingnews.comContrasting enVVeno Medical (NASDAQ:NVNO) & Invo Bioscience (OTCMKTS:IVOB)March 4, 2023 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate UpdateMarch 2, 2023 | finance.yahoo.comenVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate UpdateFebruary 8, 2023 | finance.yahoo.comenVVeno Medical to Present at Cowen's 43rd Annual Health Care ConferenceJune 4, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.February 5, 2023 | yahoo.comWe're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn RateJanuary 18, 2023 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology OfficerJanuary 18, 2023 | finance.yahoo.comenVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology OfficerJanuary 11, 2023 | finance.yahoo.comJTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19thNovember 17, 2022 | finance.yahoo.comPositive 3-Year VenoValve(R) First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular IssuesNovember 7, 2022 | finance.yahoo.comenVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal StudyOctober 27, 2022 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 27, 2022 | finance.yahoo.comenVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 14, 2022 | seekingalpha.comNVNO enVVeno Medical CorporationSeptember 23, 2022 | seekingalpha.comenVVeno Medical: Unique Exposure To Venous Treatment DomainSeptember 22, 2022 | finance.yahoo.comenVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare ConferenceSeptember 21, 2022 | finance.yahoo.comenVVeno Medical Announces the Development of a Transcatheter Based Replacement Venous Valve for the Treatment of Chronic Venous InsufficiencySeptember 19, 2022 | finance.yahoo.comenVVeno Medical to Host Conference Call and Webcast on September 21, 2022September 12, 2022 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 12, 2022 | finance.yahoo.comenVVeno Medical to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 29, 2022 | finance.yahoo.comenVVeno Medical (NASDAQ:NVNO) Is In A Good Position To Deliver On Growth PlansAugust 16, 2022 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical OperationsAugust 16, 2022 | finance.yahoo.comenVVeno Medical Appoints Kevin Belteau as Vice President of Clinical OperationsSee More Headlines NVNO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVNO Company Calendar Last Earnings8/11/2021Today6/04/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVNO CUSIPN/A CIK1661053 Webwww.hancockjaffe.com Phone(949) 261-2900Fax949-261-2992Employees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-63.50% Return on Assets-59.27% Debt Debt-to-Equity RatioN/A Current Ratio29.58 Quick Ratio29.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.60 per share Price / Book0.88Miscellaneous Outstanding Shares9,470,000Free Float7,928,000Market Cap$29.93 million OptionableNot Optionable Beta1.24 Key ExecutivesRobert Andrew BermanChief Executive Officer & DirectorCraig T. GlynnChief Financial Officer & TreasurerMarc H. GlickmanChief Medical Officer & Senior Vice PresidentHamed AlaviVice President-Research, Development & QualityKey CompetitorsAcutus MedicalNASDAQ:AFIBVapothermNYSE:VAPOBrainsWayNASDAQ:BWAYSTRATA Skin SciencesNASDAQ:SSKNCo-DiagnosticsNASDAQ:CODXView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPSold 19,968 shares on 5/16/2023Ownership: 0.456%Dimensional Fund Advisors LPBought 2,511 shares on 5/12/2023Ownership: 0.253%Francis DuhayBought 7,751 shares on 8/16/2022Total: $47,591.14 ($6.14/share)Sanjay ShrivastavaBought 1,000 shares on 6/30/2022Total: $3,850.00 ($3.85/share)Robert Andrew BermanBought 2,500 shares on 6/27/2022Total: $9,500.00 ($3.80/share)View All Insider TransactionsView All Institutional Transactions NVNO Stock - Frequently Asked Questions How have NVNO shares performed in 2023? enVVeno Medical's stock was trading at $5.10 at the beginning of 2023. Since then, NVNO stock has decreased by 38.0% and is now trading at $3.16. View the best growth stocks for 2023 here. When is enVVeno Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our NVNO earnings forecast. How were enVVeno Medical's earnings last quarter? enVVeno Medical Corporation (NASDAQ:NVNO) released its earnings results on Wednesday, August, 11th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.06. What is enVVeno Medical's stock symbol? enVVeno Medical trades on the NASDAQ under the ticker symbol "NVNO." Who are enVVeno Medical's major shareholders? enVVeno Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Susquehanna International Group LLP (0.46%) and Dimensional Fund Advisors LP (0.25%). Insiders that own company stock include Francis Duhay, Gmt Capital Corp, Holding SA Biodyne, Marc H Glickman, Matthew Jenusaitis, Robert Andrew Berman, Robert Gray and Sanjay Shrivastava. View institutional ownership trends. How do I buy shares of enVVeno Medical? Shares of NVNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is enVVeno Medical's stock price today? One share of NVNO stock can currently be purchased for approximately $3.16. How much money does enVVeno Medical make? enVVeno Medical (NASDAQ:NVNO) has a market capitalization of $29.93 million. How can I contact enVVeno Medical? enVVeno Medical's mailing address is 70 DOPPLER, IRVINE CA, 92618. The official website for the company is www.hancockjaffe.com. The company can be reached via phone at (949) 261-2900 or via fax at 949-261-2992. This page (NASDAQ:NVNO) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enVVeno Medical Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.